Stock Events

Stock Events

Thalia Therapeutics 

GBX0.49
0
+GBX0.07+15.29% Thursday 13:21

Statistics

Day High
0.49
Day Low
0.4
52W High
1
52W Low
0.35
Volume
2,445,759
Avg. Volume
555,829
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

1JanExpected
Q4 0
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow THAT.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN.LSE
Mkt Cap194.5B
GSK
GSK.LSE
Mkt Cap71.64B
Pfizer
PFE
Mkt Cap140.15B
Pfizer is a global biopharmaceutical company that competes in developing innovative medicines and vaccines, which could intersect with N4 Pharma's research and development areas.
Merck
MRK
Mkt Cap214.76B
Merck & Co., known for its research-driven pharmaceutical products, competes in the same industry, potentially overlapping with N4 Pharma's therapeutic focus.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that competes across various therapeutic areas, including those that might be of interest to N4 Pharma, such as novel drug delivery systems.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson operates in the pharmaceutical and healthcare sectors, potentially competing with N4 Pharma in areas like drug development and healthcare solutions.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines that could compete with N4 Pharma's product pipeline and research areas.
Sanofi
SNY
Mkt Cap124.45B
Sanofi is a global biopharmaceutical company that could compete with N4 Pharma in areas such as vaccine development and innovative therapeutic solutions.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie is a research-based biopharmaceutical company that competes in developing advanced therapies, which might overlap with N4 Pharma's focus on novel drug delivery technologies.
Roche
RHHBY
Mkt Cap258.9B
Roche Holding AG is involved in pharmaceuticals and diagnostics, competing in the development of innovative drugs and healthcare solutions that could be in direct competition with N4 Pharma's business model.

About

N4 Pharma Plc, a specialist pharmaceutical company, develops nanoparticle silica delivery systems to enhance the cellular delivery and potency of cancer treatments and vaccines in the United Kingdom. It develops Nuvec, a silica nanoparticle delivery system, which has an irregular surface structure that traps and protects siRNA/RNA/DNA; and Liptide, a platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The company also engages in the development of N4 101, an orally delivered inflammation inhibitor which is in the pre-clinical development for treatment of inflammatory bowel disease; and ECP105 for the prevention of ocular scarring. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.
Show more...
CEO
Mr. Nigel James Theobald
Employees
4
Country
GB
ISIN
GB00BYW8QM32

Listings

LSE
GB
THAT.LSE
LSE
GB
N4P.LSE
F
DE
0GO.F

0 Comments

Share your thoughts

FAQ

What is Thalia Therapeutics stock price today?▼
The current price of THAT.LSE is GBX0.49 GBX — it has increased by +15.29% in the past 24 hours. Watch Thalia Therapeutics stock price performance more closely on the chart.
What is Thalia Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Thalia Therapeutics stocks are traded under the ticker THAT.LSE.
How many employees does Thalia Therapeutics have?▼
As of April 05, 2026, the company has 4 employees.
In which sector is Thalia Therapeutics located?▼
Thalia Therapeutics operates in the Health Care sector.
When did Thalia Therapeutics complete a stock split?▼
Thalia Therapeutics has not had any recent stock splits.
Where is Thalia Therapeutics headquartered?▼
Thalia Therapeutics is headquartered in London, GB.